Trial Profile

A second phase 2b trial assessing VDA-1102 to treat actinic keratosis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 21 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Dec 2023 New trial record
19 Dec 2023 According to Vidac Pharma media release, the company has completed preparations for a Phase 2b trial of VDA-1102 to treat actinic keratosis (AK). The company announces that it has engaged a world-leading dermatology research institute, CentroDerm GmbH (Wuppertal, Germany), and mandated Forschungsdock Gmbh, a CRO, to perform the study. Prof. Dr. Thomas Dirschka, will be the principal investigator of the study.
19 Dec 2023 According to Vidac Pharma media release, a protocol will be finalized within two months and submitted to health authorities in Germany.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com